Want to see VIR full AI Analyst Report?
Total Valuation
Vir Biotechnology has a market cap or net worth of $1.52B. The enterprise value is $1.28K.
Market Cap$1.52B
Enterprise Value$1.28K
Share Statistics
Vir Biotechnology has 169,215,960 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding169,215,960
Owned by Insiders10.08%
Owned by Institutions29.86%
Financial Efficiency
Vir Biotechnology’s return on equity (ROE) is -0.57 and return on invested capital (ROIC) is -50.94%.
Return on Equity (ROE)-0.57
Return on Assets (ROA)-0.44
Return on Invested Capital (ROIC)-50.94%
Return on Capital Employed (ROCE)-0.51
Revenue Per Employee186.80K
Profits Per Employee-1.19M
Employee Count367
Asset Turnover0.07
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Vir Biotechnology is ―. Vir Biotechnology’s PEG ratio is 0.11.
PE Ratio―
PS Ratio12.18
PB Ratio1.09
Price to Fair Value1.09
Price to FCF-2.11
Price to Operating Cash Flow-4.63
PEG Ratio0.11
Income Statement
In the last 12 months, Vir Biotechnology had revenue of 68.56M and earned -437.99M in profits. Earnings per share was -3.16.
Revenue68.56M
Gross Profit56.85M
Operating Income-468.02M
Pretax Income-437.77M
Net Income-437.99M
EBITDA-426.09M
Earnings Per Share (EPS)-3.16
Cash Flow
In the last 12 months, operating cash flow was -334.89M and capital expenditures 3.35M, giving a free cash flow of -331.54M billion.
Operating Cash Flow-334.89M
Free Cash Flow-331.54M
Free Cash Flow per Share-1.96
Dividends & Yields
Vir Biotechnology pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.67
52-Week Price Change106.25%
50-Day Moving Average9.28
200-Day Moving Average8.21
Relative Strength Index (RSI)52.63
Average Volume (3m)2.09M
Important Dates
Vir Biotechnology upcoming earnings date is Oct 29, 2026, After Close (Confirmed).
Last Earnings DateAug 5, 2026
Next Earnings DateOct 29, 2026
Ex-Dividend Date―
Financial Position
Vir Biotechnology as a current ratio of 5.54, with Debt / Equity ratio of 9.49%
Current Ratio5.54
Quick Ratio5.54
Debt to Market Cap0.12
Net Debt to EBITDA0.11
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Vir Biotechnology has paid 217.00K in taxes.
Income Tax217.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Vir Biotechnology EV to EBITDA ratio is -1.85, with an EV/FCF ratio of -1.99.
EV to Sales11.50
EV to EBITDA-1.85
EV to Free Cash Flow-1.99
EV to Operating Cash Flow-2.01
Balance Sheet
Vir Biotechnology has $528.59M in cash and marketable securities with $93.27M in debt, giving a net cash position of $435.32M billion.
Cash & Marketable Securities$528.59M
Total Debt$93.27M
Net Cash$435.32M
Net Cash Per Share$2.57
Tangible Book Value Per Share$5.35
Margins
Gross margin is 170.01%, with operating margin of -682.68%, and net profit margin of -638.87%.
Gross Margin170.01%
Operating Margin-682.68%
Pretax Margin-638.56%
Net Profit Margin-638.87%
EBITDA Margin-621.52%
EBIT Margin-638.56%
Analyst Forecast
The average price target for Vir Biotechnology is $21.29, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$21.29
Price Target Upside144.94% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast1495.93%
EPS Growth Forecast53.66%